University of Patras
Ο ρόλος του ορφανού πυρηνικού υποδοχέα NR5A2 στις νεοπλασίες του νευρικού συστήματος
Abstract
dc:descriptionMalignancies of the nervous system are characterised by rapid progression and low survival rates. These clinical observations underline the need to explore new pharmacological targets and therapeutic approaches. Towards this goal and in the present work we identified the orphan nuclear receptor NR5A2/LRH1 as a negative regulator of tumor cell proliferation and a promising pharmacological target for nervous system-related tumors. In particular, bioinformatics analysis of gene expression data from patient tumors available in databases such as Oncomine and TCGA (The Cancer Genome Atlas) show that high levels of NR5A2 expression are associated with a favorable prognosis in patients with glioblastoma and neuroblastoma tumors. We then showed with a series of overexpression experiments that NR5A2 is sufficient to strongly suppress proliferation of both human and mouse glioblastoma and neuroblastoma cells without inducing apoptosis. In addition, suppression of NR5A2 expression, using specific shRNA vectors, promotes glioblastoma cell proliferation and cell cycle. Also, the anti-proliferative activity of NR5A2 is mediated by the transcriptional induction of the negative regulators of the cell cycle, CDKN1A (encoding p21cip1), CDKN1B (encoding p27kip1) and Prox1. In the context of pharmacological targeting of this molecule, we showed that two established agonists of NR5A2, dihydroylphosphatidylcholine (DLPC) and dinucleotidylphosphatidylcholine (DUPC), are able to mimic the anti-proliferative activity of NR5A2 in human glioblastoma cells through induction of the same critical genes. Our most important observation, however, is that one of these agonists, DLPC, is both able to cross the blood-brain barrier and suppress glioblastoma tumor growth in vivo in heterotopic and orthotopic mouse xenograft models. These data suggest a tumor suppressive role of NR5A2 in the nervous system and make this nuclear receptor a potential pharmacological target for the treatment of neural tissue-associated tumors.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkikas, Dimitrios
- Γκίκας, Δημήτριος
Subjects
dc:subject × 20- Γλοιοβλαστώματα
- Πυρηνικός υποδοχέας
- Φωσφολιπίδια
- Glioblastoma multiforme
- NR5A2
- Nuclear receptor corepressor
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία κυττάρου
- Βιοχημεία και Μοριακή βιολογία
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Biological Sciences
- Natural Sciences
- Cell Biology
- Biochemistry and Molecular Biology
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51309